Print this Page

Ground View

The majority of new therapeutics and medical products rely on almost every part of the life sciences ecosystem, from basic research to large pharmaceutical companies, from government funding organizations to venture capital. Thus, collaborations and cross-pollination are an essential part of the biomedical industry as well as an ecosystem that supports innovation at the state and federal levels.

The industry has made great strides in understanding and treating major diseases, such as cancer, as well as researching and finding new therapies for orphan diseases. Each of these strides often begins with a step into the unknown. The risk of stepping into the unknown can be more calculated and mitigated when organizations work together.

California has the largest number of emerging life sciences companies, translating new and innovative biology. New biology is essential for breakthrough medicines and diagnostics that can make substantial improvements on patients’ health.

The first snapshot, Melissa Ashlock, vice president, External Scientific Alliances and Human Genetics at aTyr Pharma, discusses her experiences at the Cystic Fibrosis Foundation working with Aurora and then Vertex on the drug discovery and development process for Kalydeco, the first drug approved to affect the underlying mechanism of cystic fibrosis.

In the second snapshot, Kim Popovits at Genomic Health discusses how new diagnostics based on genomic information is helping to personalize medicines and treatments. The lessons from these success of creating a new therapeutic and diagnostic products are important for other companies and organizations that are working at the leading edge of biology, medicine and human disease.

SNAPSHOT:
COLLABORATIONS
aTyr Pharma

aTyr Pharma
aTyr Pharma
“There are many obstacles to drug development, and thus investors have lots of reasons to avoid making big investments or taking big risks. To get around this, organizations or collaborations that develop paths for clinical evaluation of new drugs or lower risk somehow, are needed.”

Melissa Ashlock, M.D., Vice President, External Scientific Alliances and Human Genetics, aTyr Pharma

Read more…

SNAPSHOT:
COLLABORATIONS
Genomic Health

Genomic Health
Genomic Health

Kim Popovits, President and CEO, Genomic Health

Read more…

Permanent link to this article: http://www.californiabiomedreport.com/funding-translational-research-ground-view/